Integr Cancer Ther. 2009 Sep;8(3):283-7.
Sonodynamic and photodynamic therapy in advanced breast carcinoma: a report of 3 cases.
Wang X,
Zhang W,
Xu Z,
Luo Y,
Mitchell D,
Moss RW.
LINK
Source
Chemistry and Environment College, Southern China Normal University, Guangzhou, People's Republic of China.
wangxhgz@163.com
Abstract
Photodynamic therapy (PDT) is an established therapeutic method, first approved by the FDA for certain kinds of cancer in 1998. There are also increasing data to show that a related procedure, sonodynamic therapy (SDT), is a promising new modality for cancer treatment. Here, the authors report clinical results in 3 advanced refractory breast cancer patients who were treated using a combination of sonodynamic and photodynamic therapy (SPDT), along with conventional therapies. All
3 patients had pathologically proven metastatic breast carcinoma. These widely disseminated carcinomas had ultimately failed to respond to conventional therapy. A new sensitizing agent, Sonoflora 1 (SF1) was administered sublingually; then, after a 24-hour delay, patients were treated with a combination of light and ultrasound. All patients had significant partial or complete responses. SPDT is a promising new therapeutic combination for the treatment of breast cancer.
Comment in
Available at clinic in Mexico:
http://www.hope4cancer.com/treatment...t-therapy.html
http://www.sonophotodynamictherapy.com/
Quote:
What is Sono-Photo?
SPDT has been around since the 1800s, very successful, but limited by the toxicity of the agents, that were not very selective for cancer cells and very toxic, essentially forms of Chemo. In the late 1990s, non-toxic agents were developed in Russia, primarily algae/chlorophyll, launching PDT into a whole new level of non-toxic, non-invasive cancer treatment.
SPDT involves getting an agent into the whole body, (originally by injection, now orally), which adheres to cancer cells, so that when light and now, sound, of the correct frequency is applied, the agent "explodes" into free radical oxygen, instantly killing the cancer cells which cannot survive in oxygen. For total and permanent recovery, it is still necessary to address the causes and even more important to do complete cleansing of toxins from the body, especially including all of the just killed cancer cells. SPDT is recently approved in the U.S., UK, and has been adopted by the Chinese Government. Experimental projects have recently been published in Toronto, Canada and other countries.
|
Squamous Cell Cancer Responds to SPDT Therapy (press release)
http://www.prnewswire.com/news-relea...136735763.html
J Dermatol. 2000 May;27(5):294-306.
Combination effect of photodynamic and sonodynamic therapy on experimental skin squamous cell carcinoma in C3H/HeN mice.
Jin ZH,
Miyoshi N,
Ishiguro K,
Umemura S,
Kawabata K,
Yumita N,
Sakata I,
Takaoka K,
Udagawa T,
Nakajima S,
Tajiri H,
Ueda K,
Fukuda M,
Kumakiri M.
Source
Department of Dermatology, Fukui Medical University, Japan.
Abstract
We studied a combination of photodynamic therapy (PDT) and sonodynamic therapy (SDT) for improving tumoricidal effects in a transplantable mouse squamous cell carcinoma (SCC) model. Two sensitizers were utilized: the pheophorbide-a derivative PH-1126, which is a newly developed photosensitizer, and the gallium porphyrin analogue ATX-70, a commonly used sonosensitizer. Mice were injected with either PH-1126 or ATX-70 i.p. at doses of 5 or 10 mg/kg.bw. At 24 (ATX-70) or 36 hr (PH-1126) (time of optimum drug concentration in the tumor) after injection, SCCs underwent laser light irradiation (88 J/cm2 of 575 nm for ATX-70; 44J/cm2 of 650 nm for PH-1126) (PDT), ultrasound irradiation (0.51 W/cm2 at 1.0 MHz for 10 minutes) (SDT), or a combination of the two treatments. The combination of PDT and SDT using either PH-1126 or ATX-70 as a sensitizer resulted in significantly improved inhibition of tumor growth (92-98%) (additive effect) as compared to either single treatment (27-77%). The
combination using PH-1126 resulted in 25% of the treated mice being tumor free at 20 days after treatment. Moreover, the median survival period (from irradiation to death) of PDT + SDT-treated mice (> 120 days) was significantly greater than that in single treatment groups (77-95 days). Histological changes revealed that combination therapy could induce tumor necrosis 2-3 times as deep as in either of the single modalities. The combination of PDT and SDT could be very useful for treatment of non-superficial or nodular tumors.
- PMID:
- 10875195
- [PubMed - indexed for MEDLINE]
Ultrasound Med Biol. 2009 Aug;35(8):1397-404. Epub 2009 Jun 9.
Photodynamic and sonodynamic treatment by phthalocyanine on cancer cell lines.
Kolarova H,
Tomankova K,
Bajgar R,
Kolar P,
Kubinek R.
LINK
Source
Department of Medical Biophysics, Faculty of Medicine, Palacky University, Hnevotinska 3, 775 15 Olomouc, Czech Republic.
kol@tunw.upol.cz
Abstract
Photodynamic therapy is a modality of treatment for tumors. The photochemical interactions of sensitizer, light and molecular oxygen produce reactive oxygen species (ROS) such as singlet oxygen, peroxide, hydroxyl radical and superoxide ion. The tumor is destroyed either by the formation of highly reactive singlet oxygen (type II mechanism) or by the formation of radical products (type 1 mechanism) generated in an energy transfer reaction. The resulting damage to organelles within malignant cells leads to tumor ablation. The cellular effects include membrane damage, mitochondrial damage and DNA damage. A new treatment modality called sonodynamic therapy has been developed, in which the ultrasound-induced cytotoxicity of sonochemical sensitizers inhibits tumor growth. In this study, the promising new generation of sensitizers - phthalocyanines - were used to induce the photodamage. In addition, we applied an ultrasound treatment to support the photodynamic effect. We report on the production of ROS in G361 melanoma cells. Light-emitting diodes were used to evoke the photodynamic effect. Changes in cells were evaluated using fluorescence microscope and atomic force microscopy. The quantitative ROS production changes in relation to sensitizer concentration, irradiation doses and ultrasound intensity were proved by a fluororeader. Our results showed the highest generation of ROS within G361 melanoma cells was achieved at an irradiation dose of 15 Jcm(-2) followed by ultrasound treatment at intensity of 2 Wcm(-2) and frequency of 1 MHz in the presence of 100 muM chloroaluminum phthalocyanine disulfonate (ClAlPcS2). These results suggest that ClAlPcS2 is a potential photosensitizer and sonosensitizer for sonodynamic or photodynamic treatment of cancer.
- PMID:
- 19515482
- [PubMed - indexed for MEDLINE]
Physiol Res. 2007;56 Suppl 1:S27-32. Epub 2007 May 31.
In vitro study of reactive oxygen species production during photodynamic therapy in ultrasound-pretreated cancer cells.
Kolárová H,
Bajgar R,
Tománková K,
Krestýn E,
Dolezal L,
Hálek J.
Source
Department of Medical Biophysics, Faculty of Medicine, Palacký University, Olomouc, Czech Republic.
kol@tunw.upol.cz
FREE TEXT
Abstract
Several recent studies bring evidence of cell death enhancement in photodynamic compound loaded cells by ultrasonic treatment. There are a number of hypotheses suggesting the mechanism of the harmful ultrasonic effect. One of them considers a process in the activation of photosensitizers by ultrasonic energy. Because the basis of the photodynamic damaging effect on cells consists in the production of reactive oxygen species (ROS), we focused our study on whether the ultrasound can increase ROS production within cancer cells. Particularly,
we studied ROS formation in ultrasound pretreated breast adenocarcinoma cells during photodynamic therapy in the presence of chloroaluminum phthalocyanine disulfonate (ClAlPcS2). Production of ROS was investigated by the molecular probe CM-H2DCFDA. Our results show that ClAlPcS2 induces higher ROS production in the ultrasound pretreated cell lines at a concentration of 100 microM and light intensity of 2 mW/cm2. We also observed a dependence of ROS production on photosensitizer concentration and light dose. These results demonstrate that the photodynamic effect on breast cancer cells can be enhanced by ultrasound pretreatment.
- PMID:
- 17552898
- [PubMed - indexed for MEDLINE]
Toxicol In Vitro. 2007 Oct;21(7):1304-6. Epub 2007 Sep 5.
Sensitivity of different cell lines to phototoxic effect of disulfonated chloroaluminium phthalocyanine.
Kolarova H,
Lenobel R,
Kolar P,
Strnad M.
LINK
Source
Department of Medical Biophysics, Faculty of Medicine, Laboratory of Growth Regulators, Palacky University, HnevotÃ*nská 3, 775 15 Olomouc, Czech Republic.
kol@tunw.upol.cz
Abstract
Photodynamic therapy (PDT) is a treatment for cancer involving three key components: sensitizer, light and tissue oxygen. A sensitizer is a chemical compound that can be excited by light of a specific wavelength. Phthalocyanine ClAlPcS(2), belonging among the promising second generation of sensitizers, was evaluated as an inducer of photodamage on NIH3T3 (mouse fibroblasts), B16 (mouse melanoma), MCF7 (human breast adenocarcinoma) and G361 (human melanoma) cell lines. A semiconductor laser was used as a source for evocation of the photodynamic effect. We report the influence of various concentrations of the sensitizer in combination with laser irradiation on the photodamage of cells. Viability of cells was determined by means of molecular probes (Calcein AM and ethidium homodimer) for fluorescence microscopy. The quantitative changes of cell viability in relation to sensitizer concentrations and laser irradiation were proved by fluorometric measurement.
We detected phototoxicity evoked by laser irradiated sensitizer in all studied cell lines. In addition, the viability studies showed that G361 melanoma cells and MCF7 breast adenocarcinoma cells were more sensitive than NIH3T3 mouse fibroblasts and B16 mouse melanoma to photodynamic damage induced by ClAlPcS(2).
- PMID:
- 17923379
- [PubMed - indexed for MEDLINE]
-
Linear Mode
